The substantial beat on both EPS and sales estimates for Q1 indicates a robust financial performance by Protagonist Therapeutics. Such positive earnings reports typically lead to increased investor confidence and can drive the stock price up in the short term. The magnitude of the beat suggests operational efficiency and potentially higher future profitability, factors that are likely to be viewed favorably by the market.